Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
Gam1983/Getty Images
#Lilly #weightloss #pill #orforglipron #FDA #approval #CEO #Dave #Ricks